ORABASE HCA Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Orabase Hca, and what generic alternatives are available?
Orabase Hca is a drug marketed by Colgate and is included in one NDA.
The generic ingredient in ORABASE HCA is hydrocortisone acetate. There are sixty-seven drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the hydrocortisone acetate profile page.
Summary for ORABASE HCA
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 90 |
Clinical Trials: | 9 |
Patent Applications: | 3,921 |
Formulation / Manufacturing: | see details |
DailyMed Link: | ORABASE HCA at DailyMed |
Recent Clinical Trials for ORABASE HCA
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Mona Taha Mohammed MD | Early Phase 1 |
Cairo University | N/A |
Beni-Suef University | Phase 1 |
Anatomical Therapeutic Chemical (ATC) Classes for ORABASE HCA
US Patents and Regulatory Information for ORABASE HCA
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Colgate | ORABASE HCA | hydrocortisone acetate | PASTE;TOPICAL | 083205-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |